English  |  正體中文  |  简体中文  |  Items with full text/Total items : 90068/105181 (86%)
Visitors : 7148989      Online Users : 67
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/4567


    Title: Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival
    Authors: Yuh-Pyng Sher;Tz-Fei Tzeng;Shu-Fen Kan;Jennifer Hsu;Xiaoming Xie;Zhenbo Han;Wen-Chuan Lin;Long-Yuan Li;Mien-Chie Hung
    Keywords: targeted gene therapy;lung cancer;BiKDD;VISA;survivin
    Date: 2009-07
    Issue Date: 2009-11-27 13:56:51 (UTC+8)
    Publisher: Asia University
    Abstract: Lung cancer is a leading cause of cancer death due to the
    high incidence of metastasis; therefore, novel and effective
    treatments are urgently needed. A current strategy is
    cancer-specific targeted gene therapy. Although many
    identified that cancer-specific promoters are highly
    specific, they tend to have low activity compared with
    the ubiquitous cytomegalovirus (CMV) promoter, limiting
    their application. We developed a targeted gene therapy
    expression system for lung cancer that is highly specific
    with strong activity. Our expression vector uses the
    survivin promoter, highly expressed in many cancers but
    not normal adult tissues. We enhanced the survivin
    promoter activity comparable to the CMV promoter in
    lung cancer cell lines using an established platform
    technology, whereas the survivin promoter remained weak
    in normal cells. In mouse models, the transgene was
    specifically expressed in the lung tumor tissue, compared
    with the CMV promoter that was expressed in both
    normal and tumor tissues. In addition, the therapeutic
    gene BikDD, a mutant form of pro-apoptotic Bcl2
    interacting killer, induced cell killing in vitro, and
    inhibited cell growth and prolonged mouse survival
    in vivo. Importantly, there was virtually no toxicity when
    BikDD was expressed with our expression system. Thus,
    the current report provides a therapeutic efficacy and safe
    strategy worthy of development in clinical trials treating
    lung cancer
    Relation: ONCOGENE 28:3286?3295
    Appears in Collections:[生物科技學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    0KbUnknown382View/Open
    144.doc39KbMicrosoft Word442View/Open


    All items in ASIAIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback